Fresenius Medical Care receives FDA clearance for 2008T hemodialysis delivery system

NewsGuard 100/100 Score

At the American Society of Nephrology's Kidney Week 2011, Fresenius Medical Care (NYSE: FMS), the world's largest provider of dialysis products and services, announced that it received U.S. Food and Drug Administration 510 (K) clearance to extend improved touch screen navigation on its most advanced hemodialysis delivery system, the 2008T. Effective immediately, all newly produced 2008T machines with Fresenius Clinical Data Exchange (CDX) will come with this enhancement.

Introduced a year ago at Kidney Week 2010, the 2008T is the first fully integrated therapy and management information system on the market. The 2008T combines Fresenius Medical Care's most advanced hemodialysis delivery system with CDX providing caregivers, for the first time, chair-side access to the facility's medical information system and dialysis treatment data.

"With all the key information a medical professional needs, immediately at hand, they can focus on patient care. The human factors engineering is an appreciation of how medical professionals actually work in the clinical setting. The 2008T puts key patient and treatment information more quickly at the clinicians' fingertips," said Jose A. Diaz-Buxo, MD, FACP, Chief Medical & Regulatory Affairs Officer, Fresenius Medical Care. "Simplicity, ease of use and readily available information allows care-givers more time to focus on the patient."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Renaissance of "food as medicine" in modern clinical trials